BioSpace News Archive

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced that new research performed in the laboratory of preeminent CD4 T cell researcher, Andrea Sant, PhD at the University of Rochester Center for Vaccine Biology and Immunology, was published in the peer-reviewed journal, Viruses.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.

The Terasaki Institute for Biomedical Innovation is proud to announce the final agenda for its Terasaki Innovation Summit, taking place on March 8th - 10th at the UCLA Meyer & Renee Luskin Center.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today presented its Phase 2 clinical trial in progress of lead therapeutic candidate, PT-112, in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC).

INOVIO (NASDAQ: INO) today announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

Incyte announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. in Boston.

Sesen Bio, Inc. announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. management team on Tuesday, February 21, 2023, at 8:00 am ET.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath’s new Chairman.

Biora Therapeutics, Inc. announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a variant of adalimumab.